Navigation Links
Clinical sequencing technology identifies new targets in diverse cancers
Date:6/7/2013

PHILADELPHIA Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

FGFR genes are receptors that bind to members of the fibroblast growth factor family of proteins and play a role in key biological processes of a human cell. Because of a chromosomal abnormality, this gene sometimes fuses with another gene and forms a hybrid, or a gene fusion, resulting in a gene product with an entirely different function, causing cancers.

"We found targetable FGFR gene fusions across a diverse array of cancer types. Although rare for any individual cancer type, if found in an individual patient, these fusions are likely a major driver of that patient's cancer," said Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology at the University of Michigan in Ann Arbor. "We were surprised to find so many different FGFR fusions in so many different cancers.

"This study demonstrates the benefit of broad-based sequencing efforts in personalized oncology. It has the potential to identify novel, rare mutations that are 'actionable' therapeutic targets," Chinnaiyan added. "Such advances in sequencing technology facilitate rational precision therapies for individuals with late-stage cancer."

The Michigan Oncology Sequencing Program (MI-ONCOSEQ) facilitates integrative sequencing analysis of tumors from patients with advanced cancers. More than 100 patients have been enrolled since 2011. Through the project, researchers analyze the mutational landscape of each patient's tumor and suggest clinical trials or approved drugs that might be appropriate for that patient, according to Chinnaiyan.


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Prescription hCG Diet Plans Now With Unlimited Clinical Support For All Patients
2. African Mango Plus is Clinically Proven Effective Formula to Increase the Energy Level of the Body
3. AAOS releases revised clinical practice guideline for osteoarthritis of the knee
4. HealthCarePoint Pledges More Than $10 Million in Software and Technology Services to Help Support ACRES Global Network for Clinical Research
5. NIH to fund clinical research network on antibacterial resistance
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. Back2Basics Outdoor Adventures Names John Valvo as New Clinical Director
9. ATS publishes clinical practice guidelines on sleep apnea and driving
10. Medstreaming Appoints Vascular Health Care Veteran Keith Fujioka as VP of Clinical Services
11. CureLauncher Introduces Personalized Clinical Trial Matching Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2
... exposure can produce more than some tanners may bargain ... to treat skin eruptions, according to research conducted by ... "There are many reasons to be cautious ... beds to ,self-treat, skin eruptions," said Jeffrey B. Travers, ...
... small subset of normal white blood cells in the body ... The study, led by investigators at The Ohio State ... and Richard J. Solove Research Institute (OSUCCC James), shows ... subset of white blood cells called NKT cells. NKT cells ...
... , CHAMPAIGN, lll. A review of more than 160 ... compelling evidence" that all else being equal happy ... their unhappy peers. The study, in the journal ... review so far of the evidence linking happiness to health ...
... (HealthDay News) -- The use of virtual colonoscopies at U.S. ... not covered by Medicare, a new study finds. Also ... uses virtual reality technology to provide doctors with a 3-D ... entire colon and rectum. CTC is an alternative to colonoscopy ...
... WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology ... marked impact on the therapeutic and diagnostic measures available ... a meterto achieve tasks that would be difficult at ... and can enter cells, making them useful for drug ...
... been on the rise in the United States. In fact, ... vehicle crash fatalities to become the leading cause of injury ... reported, they are only the tip of the iceberg. ... Research and Policy of The Research Institute at Nationwide Children,s ...
Cached Medicine News:Health News:Tanning bed exposure can be deadly when complicated by medication reactions 2Health News:A small subset of normal white blood cells gives rise to a rare leukemia, study shows 2Health News:Study: Happiness improves health and lengthens life 2Health News:Surgeons predict the future of nanomedicine in practice 2Health News:New study: Medical and financial impact of drug-related poisonings treated in US EDs 2
(Date:1/15/2014)... /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from ... China,s orthopedic instrument industry has seen ... rising from 3.28 billion yuan in 2006 to 9.85 ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Through Joint Venture Between Bristol-Myers Squibb and ... Its Kind in HIV Treatment -, PRINCETON, N.J. ... Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 mg/emtricitabine ... commercialization in the,27 countries of the European Union, as ...
... novel combination of drugs was,able to completely eradicate ... for the effective treatment of patients with advanced,metastatic ... University,School of Medicine presented the results of a ... pulmonary metastases in female SCID,mice., Paclitaxel is ...
Cached Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9New Drug Combination is Able to Eradicate Breast Metastases in Mice 2